Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRabanal Anglada, Francesc-
dc.contributor.authorCajal Visa, Yolanda-
dc.description.abstractThe rise of bacterial pathogens with acquired resistance to almost all available antibiotics is becoming a serious public health issue. Polymyxins, antibiotics that were mostly abandoned a few decades ago because of toxicity concerns, are ultimately considered as a last-line therapy to treat infections caused by multi-drug resistant Gram-negative bacteria. This review surveys the progress in understanding polymyxin structure, chemistry, mechanisms of antibacterial activity and nephrotoxicity, biomarkers, synergy and combination with other antimicrobial agents and antibiofilm properties. An update of recent efforts in the design and development of a new generation of polymyxin drugs is also discussed. A novel approach considering the modification of the scaffold of polymyxins to integrate metabolism and detoxification issues into the drug design process is a promising new line to potentially prevent accumulation in kidney and reduce nephrotoxicity-
dc.format.extent23 p.-
dc.publisherRoyal Society of Chemistry-
dc.relation.isformatofVersió postprint del document publicat a:
dc.relation.ispartofNatural Product Reports, 2017, vol. 34, num. 7, p. 886-908-
dc.rights(c) Rabanal Anglada, Francesc et al., 2017-
dc.subject.classificationMedicaments antibacterians-
dc.subject.classificationEstructura molecular-
dc.subject.otherAntibacterial agents-
dc.subject.otherMolecular structure-
dc.titleRecent advances and perspectives in the design and development of polymyxins-
Appears in Collections:Articles publicats en revistes (Química Inorgànica i Orgànica)

Files in This Item:
File Description SizeFormat 
671850.pdf2.79 MBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.